Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities

Drug Metab Lett. 2009 Apr;3(2):67-9. doi: 10.2174/187231209788654036.

Abstract

Changes in lipids and lopinavir plasma concentrations were examined in 40 HIV-patients exposed to lopinavir/ritonavir 400/100 mg BID, formulated as tablets and as capsules. Triglycerides and total/HDL-cholesterol ratio were significantly lower with tablets than with capsules. Lopinavir concentrations were higher with tablets than with capsules.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Capsules
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, HDL / drug effects
  • Drug Combinations
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / pharmacokinetics*
  • Humans
  • Lopinavir
  • Male
  • Middle Aged
  • Pyrimidinones / administration & dosage
  • Pyrimidinones / adverse effects
  • Pyrimidinones / pharmacokinetics*
  • Retrospective Studies
  • Ritonavir / administration & dosage
  • Ritonavir / adverse effects
  • Tablets
  • Triglycerides / blood

Substances

  • Capsules
  • Cholesterol, HDL
  • Drug Combinations
  • HIV Protease Inhibitors
  • Pyrimidinones
  • Tablets
  • Triglycerides
  • Lopinavir
  • Cholesterol
  • Ritonavir